Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 6/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.53 |
| ▸ | CNR1 | P21554 | 1/20 | 0.53 |
| ▸ | CNR2 | P34972 | 1/20 | 0.53 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.51 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.49 |
| ▸ | ITGA1 | P56199 | 1/20 | 0.48 |
| ▸ | PGR | P06401 | 1/20 | 0.48 |
| ▸ | ELANE | P08246 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6032445 | 0.87 | SRD5A2 (0.72) | SRD5A2POLBPARP10HPGD | |
| SCHEMBL19317526 | 0.87 | SRD5A2 (0.78) | SRD5A2POLBPARP10MCL1ELANE | |
| SCHEMBL6521756 | 0.87 | SRD5A2 (0.62) | SRD5A2POLBPARP10SERPINE1PGR | |
| SCHEMBL13599782 | 0.85 | SRD5A2 (0.88) | SRD5A2POLBPARP10ELANEAKR1C3 | |
| SCHEMBL1082112 | 0.85 | SRD5A2 (0.88) | SRD5A2POLBPARP10ELANEAKR1C3 | |
| SCHEMBL9536469 | 0.85 | SRD5A2 (0.88) | SRD5A2POLBPARP10ELANEAKR1C3 | |
| SCHEMBL2866068 | 0.85 | SRD5A2 (0.88) | SRD5A2POLBPARP10ELANEAKR1C3 | |
| SCHEMBL235530 | 0.85 | SRD5A2 (0.88) | SRD5A2POLBPARP10ELANEAKR1C3 | |
| SCHEMBL6425494 | 0.84 | SRD5A2 (0.67) | SRD5A2POLBELANEHPGD | |
| SCHEMBL23559522 | 0.83 | SRD5A2 (0.62) | SRD5A2POLBPARP10AKR1C3HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2390241-B1 | METHOD FOR MANUFACTURING CONJUGATED AROMATIC COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2014-10-01 | — | — | EP | disclosed |
| US-8598349-B2 | Method for manufacturing conjugated aromatic compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-12-03 | — | — | US | disclosed |
| EP-2390241-A1 | METHOD FOR MANUFACTURING CONJUGATED AROMATIC COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2011-11-30 | — | — | EP | disclosed |
| US-20110275859-A1 | METHOD FOR MANUFACTURING CONJUGATED AROMATIC COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED | 2011-11-10 | — | — | US | disclosed |
| US-20110256790-A1 | THERMAL INSULATION CONTAINING SUPPLEMENTAL INFRARED RADIATION ABSORBING MATERIAL | SAINT-GOBAIN ISOVER (FR) | 2011-10-20 | — | — | US | disclosed |
| EP-0773249-B1 | Polyphenylene co-polymers | MISSISSIPPI POLYMER TECHNOLOGI (US) | 2002-10-02 | — | — | EP | disclosed |
| US-5886130-A | THE CO-POLYMERS ARE USEFUL AS MOLDING RESINS, AND COMPOSITE MATRIX RESINS, AND WHERE AR IS HETEROARYLENE AS ION EXCHANGE RESINS. | MAXDEM INCORPORATED (US) | 1999-03-23 | — | — | US | disclosed |
| EP-0773249-A1 | Polyphenylene co-polymers | MAXDEM INCORPORATED (US) | 1997-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275859-A1 | METHOD FOR MANUFACTURING CONJUGATED AROMATIC COMPOUND | C9, H1-10, CYP1A1 | SRD5A2 3817/4885POLB 3065/4885PARP10 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.